As part of our ongoing commitment to reliability, accessibility, and quality in the healthcare supply chain, SCA Pharma is pleased to announce an expanded distribution approach for our core pharmaceutical products. Healthcare professionals can now access SCA Pharma’s trusted offerings through a broader network of purchasing platforms, including Medigi as an alternate location. This important…
Details
Pharmacy reliability is at the core of every successful pharmacy operation. Pharmacy leaders face intense pressure to keep daily operations running smoothly every order, every dose, and every delivery matters. But what truly sets a supplier apart isn’t just policies or promises; it’s what happens when real-life challenges enter the picture. At SCA Pharma, we…
Details
Product development in 503B outsourcing facilities involves a detailed, highly regulated process. Every compounded medication produced by facilities like SCA Pharma must be safe, compliant, and aligned with the needs of healthcare institutions. This blog dives deeper into the product development process, covering each phase from discovery to post-launch monitoring. The Product Development Process The development…
Details
In the fast-paced healthcare environment, access to critical medications is essential for providing timely, effective patient care. Ensuring the right medications are on hand when needed can be a logistical challenge for hospital pharmacies. This is where a reliable 503B outsourcing facility offering a “Buy & Ship Now” option becomes invaluable. By allowing hospital pharmacies…
Details
Windsor, CT, November 1, 2022– SCA Pharma, a nationally recognized leader in the 503B compounded pharmaceuticals outsourcing industry, providing quality, service, and value to hospitals nationwide, has announced today that Vizient has awarded a multi-year agreement to the company for its full range of 503B ready-to-use products. Vizient is one of the nation’s leading health…
Details
Last winter, as the US hospital system became overwhelmed with COVID-19 cases related to the Omicron strain, facilities across the country were forced to postpone elective surgeries to free up hospital beds. Similar to what happened following the initial outbreak of the pandemic in 2020, patients are now returning to the operating room to have…
DetailsOn January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…
Details
SCA is proud to be a Gold Sponsor for Pharmacy, Purchasing & Products’ upcoming webinar on FDA inspection trends for 503B compounders. This webinar starts promptly on Friday, January 28, 2022, at 1:00pm EST and features insights from Lou Diorio, RPh, FAPhA. To register for the event and learn more about the long-term trends and…
Details
SCA Pharma Director of Corporate Quality Racheal Adams, will join leading industry experts for the FDA’s 2021 Compounding Quality Center of Excellence Virtual Conference titled “Culture of Quality” being held September 13-15. The virtual conference will bring together outsourcing facilities, regulators and industry leadership to engage on emerging industry topics and best practices to improve…
Details
SCA will be sharing details about our quality.
Details